Increased expression of CSC markers and transcription factors, such as CD44, KIT Proto-Oncogene (KIT, CD117), POU Class 5 Homebox 1 (POU5F1, OCT4), and NANOG, was observed in ovarian cancer cells treated by cisplatin or paclitaxel both in vitro and in vivo [14–16]. This evidence concerns the gene POU5F1 and ovarian cancer.